Table 2 Comparison of clinical manifestations between AML patients and Foxo3 expression

Sex, male/female

40/26

34/22

Median age, years (range)

59 (15–87)

54.5 (10–93)

Median WBC, ×10⁹/L (range)

14.5 (0.8–528)

26.75 (0.3–197)

Median hemoglobin, g/L (range)

74.5 (34–138)

78.5 (49–135)

Median platelets, ×10⁹/L (range)

41 (3–264)

39.5 (5–415)

BM blasts, % (range)

46.25 (5.5–99)

42 (1–94.5)

CR (−/+)

33/30

29/24

FAB classification

 M₀

1 (1.5%)

0 (0%)

 M₁

6 (9.1%)

2 (3.6%)

 M₂

29 (43.9%)

19 (33.9%)

 M₃

8 (12.2%)

15 (26.8%)

 M₄

13 (19.7%)

12 (21.4%)

 M₅

8 (12.1%)

7 (12.5%)

 M₆

1 (1.5%)

1 (1.8%)

Karyotype classification

 Favorable

18 (27.3%)

19 (33.9%)

 Intermediate

37 (56.1%)

28 (50%)

 Adverse

8 (12.1%)

7 (12.5%)

 No data

3 (4.5%)

2 (3.6%)

Karyotype

 normal

27 (40.9%)

20 (35.7%)

 t(8;21)

8 (12.1%)

4 (7.1%)

 t(15;17)

9 (13.6%)

15 (26.8%)

 11q23

0 (0)

0 (0)

 complex

8 (12.1%)

5 (8.9%)

 others

11 (15.2%)

10 (30.4%)

 No data

3 (4.5%)

2 (3.6%)

 CEBPA (+/−)

10/51

3/41

 NPM1 (+/−)

4/57

3/41

 FLT3-ITD (+/−)

7/54

5/39

 KIT (+/−)

2/59

2/42

 N/K-RAS (+/−)

8/53

2/42

 IDH1/2 (+/−)

2/59

2/42

 DNMT3A (+/−)

4/57

5/39

 U2AF1 (+/−)

2/59

1/43